HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Respironics licenses obstructive sleep apnoea (OSA) treatment technology:

This article was originally published in Clinica

Executive Summary

DeVilbiss Health Care (US) will utilise Respironics' patented bi-level airway pressure technology under the terms of a North American licensing agreement announced by the two companies in January. Respironics will receive royalties on sales of DeVilbiss products incorporating the obstructive sleep apnoea (OSA) treatment technology, for which patents were awarded in July 1995. Respironics recently filed a patent infringement suit against AirSep, which had announced its intention to market a bi-level device that Respironics believes is "a clear violation" of its patents in the sector.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT083531

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel